Inversago

News

Sales of its obesity therapies may be accelerating, but Novo Nordisk is showing no signs of pushing the brake pedal on investments in the category.

Oncology

Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.